Shots:

• Edgewise has dosed the first patient in the P-II (CIRRUS-HCM) study of EDG-7500, assessing the safety, PK, and PD in patients (≤30 adults) with obstructive HCM. The patient in Part A of the study will receive EDG-7500 as a single oral dosage, and in Part B, the company expects to administer EDG-7500 as multiple oral doses (=28 days)
• EDG-7500 is an oral, selective cardiac sarcomere modulator that works by reducing early contraction velocity and treating poor cardiac relaxation in HCM and other diastolic dysfunction conditions
• Single dose arm data of EDG-7500's P-II and P-I study is anticipated in Q3'24 and also expects to initiate 28-day study in obstructive and non-obstructive HCM patients in H2'24. To begin the open-label extension trial of EDG-7500 in Q4'24

Ref: Edgewise Therapeutics | Image: Edgewise Therapeutics

Related News:- Edgewise Therapeutics Reports 6-Month Interim (ARCH) Study Results of EDG-5506 for Becker Muscular Dystrophy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com